ClinicalTrials.gg
CompletedNCT03382639Updated Feb 28, 2024Results posted

A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

A Phase 2 interventional study of Luvadaxistat and Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Completed at 54 sites in 8 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Enrollment
6th of 16
256 · median 165
Started
2018
with 1 other
Phase 2
6 of 16
1 open now
Registered
5th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 2, and was the 5th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether add-on luvadaxistat is superior to placebo on the Positive and Negative Syndrome Scale Negative Symptom Factor Score (PANSS NSFS).

Read the detailed description

The drug being tested in this study is called luvadaxistat. Luvadaxistat is being tested to treat negative symptoms in participants who have schizophrenia.

Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups in the double-blind period-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Luvadaxistat 50 mg once daily
  • Luvadaxistat 125 mg once daily
  • Luvadaxistat 500 mg once daily
  • Placebo once daily
03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a current diagnosis of schizophrenia as defined by the Mini International Neuropsychiatric Interview (MINI) 7.0.2 for Psychotic Disorders for the , Fifth Edition (DSM-5) and the general psychiatric evaluation.
  2. Initial diagnosis must be greater than or equal to (>=1) year from screening.
  3. Is receiving primary background antipsychotic therapy (other than clozapine) at a total daily dose between 2 and 6 mg of risperidone equivalents. Concomitant treatment with a sub-therapeutic dose of a second antipsychotic may be permitted with sponsor or designee approval if used to treat specific symptoms, such as insomnia or anxiety (for example, quetiapine 25-50 mg or its equivalent as needed for anxiety), but not if it is used for positive psychosis symptoms.
  4. Is treated with a stable regimen of psychotropic medications with no change (no increase in dose, less than or equal to [\<=] 25 percent [%] decrease in dose for tolerability) in the prescribed dose for 2 months before the screening visit and no dose adjustment is anticipated throughout study participation up to the Day 84/early termination visit.
  5. Has a BNSS total score (12-item, excluding number 4) >=28; stable Single-blind Placebo Run-in and baseline BNSS total (12-item, excluding number 4) scores (\<= 20% change from the screening score).
  6. Has no more than moderate-severe (\<=5) rating on PANSS positive symptom items P1, P3, P4, P5, P6, or unusual thought content (G9), with a maximum of 2 of these items rated '5'; no more than moderate (\<=4) rating on conceptual disorganization (P2).
  7. There is evidence that the participant has stable symptomatology >=3 months prior to the screening visit (example, no hospitalizations for schizophrenia, no emergency room admission due to symptoms of schizophrenia, no increase in level of psychiatric care due to worsening of symptoms of schizophrenia).
  8. Have an adult informant who will be able to provide input for completing study rating scales, including the PANSS and SCoRS (for example, a family member, social worker, caseworker, residential facility staff, or nurse who spends >=4 hours/week with the participant) and is considered reliable by the investigator. The informant must be able and willing to provide written and to participate in at least 1 in-person interview, then be able to provide continuing input by attending each clinical assessment visit or via participating in a telephone interview for other study visits that include the PANSS or SCoRS endpoints.

Exclusion criteria

Exclusion Criteria:

  1. Has a lifetime diagnosis of schizoaffective disorder; a lifetime diagnosis of bipolar disorder; or a lifetime diagnosis of obsessive compulsive disorder based on the MINI combined with the general psychiatric evaluation.
  2. Has a recent (within the last 6 months) occurrence of panic disorder, depressive episode, or other comorbid psychiatric conditions currently requiring clinical attention based on the MINI for and the general psychiatric evaluation.
  3. Has a diagnosis of substance use disorder (with the exception of nicotine dependence) within the preceding 6 months based on the MINI for DSM-5 and the general psychiatric evaluation.
  4. Is participating in a formal structured nonpharmacological psychosocial therapeutic treatment program (cognitive remediation, cognitive-behavioral therapy, intensive symptom/vocational rehabilitation) for a duration of less than (\<) 3 months before randomization. In addition, initiation of such nonpharmacological treatment programs is not permitted during study participation through the Day 84 visit.
  5. The participant exhibits more than a minimal level of antipsychotic-induced parkinsonism symptoms, as documented by a score on the modified Simpson Angus Scale (SAS) (excluding item number 10, Akathisia) greater than (>) 6.
  6. Has evidence of depression as measured by a Calgary Depression Scale Score (CDSS) > 9.
  7. Is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property, or the participant has attempted suicide within the past year prior to screening. Participants who have positive answers on item number 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) (based on the past year) prior to randomization are excluded.
  8. Has a history of brain trauma associated with loss of consciousness for >15 minutes.
  9. Diagnosis of schizophrenia occurred prior to 12 years of age.
  10. Has received electroconvulsive therapy within 6 months (180 days) before Screening.
  11. Has a history of developmental intellectual disability or mental retardation.
  12. Antipsychotic plasma levels for the participant's primary background antipsychotic are below the minimum acceptable concentration criteria per the Antipsychotic Reference document at the screening or placebo run-in visits. This criterion is not applicable to participants on a primary background antipsychotic for which a clinical assay is unavailable.
  13. Is treatment resistant. Treatment resistance is defined as prior nonresponse of positive symptoms of schizophrenia to 2 courses of treatment with antipsychotics of different chemical classes for at least 4 weeks, each at doses considered to be effective.
  14. Does not have a stable residence or is homeless.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Luvadaxistat 50 milligrams (mg)

    Participants received luvadaxistat 50 mg orally once daily (QD) for 12 weeks (Days 1 to 84).

    Drug: Luvadaxistat

  • Experimental
    Luvadaxistat 125 mg

    Participants received luvadaxistat 125 mg orally QD for 12 weeks (Days 1 to 84).

    Drug: Luvadaxistat

  • Experimental
    Luvadaxistat 500 mg

    Participants received luvadaxistat 500 mg orally QD for 12 weeks (Days 1 to 84).

    Drug: Luvadaxistat

  • Placebo comparator
    Placebo

    Participants received placebo (matching luvadaxistat) orally QD for 12 weeks (Days 1 to 84).

    Drug: Placebo

Interventions

  • TAK-831 tablets.

    Also known as: TAK-831, NBI-1065844

  • DrugPlacebo

    Luvadaxistat placebo-matching tablets.

06

What researchers measure

Primary outcomes

  1. Change From Baseline on the PANSS NSFS at Week 12

    PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS NSFS subscale consists of 7 items which assess the negative symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as least squares (LS) mean change from baseline at Week 12, determined using a mixed model for repeated measures (MMRM). A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline on the PANSS NSFS at Week 4 and Week 8

    PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS NSFS subscale consists of 7 items which assess the negative symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Weeks 4 and 8, determined using a MMRM. A negative change from baseline indicates improvement.

    Time frame: Baseline and Weeks 4 and 8

  2. Change From Baseline on the Brief Negative Symptom Scale (BNSS) Total Score (12-item) at Week 12

    The BNSS is a 13-item instrument that measures 5 domains of negative symptoms: blunted affect, alogia, asociality, anhedonia and avolition. All items in the BNSS are rated on a 7-point (0-6) scale, with anchor points generally ranging from symptoms being absent (0) to severe (6). Here, the BNSS total score (12-item, excluding item 4) was calculated by summing the 12 individual items; total score range of 0 to 72, where a higher score indicates higher severity of negative symptoms. Participants required a BNSS total score ≥28 to be eligible for the study (excluding item 4). Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

  3. Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Week 12

    BACS is a cognition assessment battery and includes brief assessments of reasoning and problem solving, verbal fluency, attention, verbal memory, working memory and motor speed. The primary measure from each test is standardized by creating T-scores whereby the mean of the test session of a healthy person is set to 50 and the standard deviation set to 10. A composite T-score is calculated by averaging the 6 standardized primary measures. The composite T-score indicates how much higher or lower the participants cognition is compared to a healthy person. Lower T-scores are indicative of lower cognitive performance. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Day 12, determined using a MMRM.

    Time frame: Baseline and Week 12

  4. Change From Baseline on the Clinical Global Impression-Schizophrenia Severity (CGI-SCH-S) Negative Symptoms Score at Week 12

    The CGI-SCH scale is an adapted version of the CGI scale that is designed to assess global illness status in participants with schizophrenia. CGI-SCH-S is a 7-point scale that requires the investigator to rate the severity of the participant's illness at the time of assessment. Here, CGI-SCH-S negative symptoms score assesses the severity of illness for negative symptoms on the following 7-point scale: 1. normal, not at all ill; 2. borderline mentally ill; 3. mildly ill; 4. moderately ill; 5. markedly ill; 6. severely ill; or 7. among the most extremely ill. Baseline was defined as the last observed value before the first dose of study treatment. The number of participants with each CGI-SCH-S negative symptoms score at baseline and at Week 12 is reported.

    Time frame: Baseline and Week 12

  5. Clinical Global Impression Schizophrenia Improvement (CGI-SCH-I) Negative Symptoms Score at Week 12

    The CGI-SCH-I assesses the participant's improvement (or worsening). CGI-SCH-I requires the investigator to assess the participant's condition relative to baseline on a 7-point scale. Here, CGI-SCH-I negative symptoms score assesses the improvement for negative symptoms on the following scale: very much improved; 2. much improved; 3. minimally improved; 4. no change; 5. minimally worse; 6. much worse; or 7. very much worse. Baseline was defined as the last observed value before the first dose of study treatment. The number of participants with each CGI-SCH-I negative symptoms score at Week 12 is reported.

    Time frame: Baseline up to Week 12

  6. Change From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Score at Week 12

    The SCoRS is an interview-based measure of cognitive functioning that is developed to specifically assess aspects of cognitive functioning in participants with schizophrenia. The items assess the 7 cognitive domains of attention, memory, reasoning and problem solving, working memory, processing speed, language functions and social cognition. The SCoRS total score is the sum of the 20 items and varies from 20 to 80 with 20 being the best outcome and 80 being the worst. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM.

    Time frame: Baseline and Week 12

  7. Change From Baseline on the PANSS Total Score at Week 12

    PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

  8. Change From Baseline on the PANSS Positive Symptom Factor Score (PSFS) at Week 12

    PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS PSFS subscale consists of 7 items which assess the positive symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

  9. Luvadaxistat Plasma Concentrations

    Blood samples were collected at pre-specified timepoints and plasma concentrations of luvadaxistat were measured. At Week 4, assessments were categorized as pre-dose or post-dose according to actual sampling time. Due to this, some participants may have had more than 1 record summarized for Week 4 pre-dose or Week 4 post-dose. Mean concentration on each visit was averaged from the observations over the time span of 24 hours post-dose or pre-dose.

    Time frame: Pre-dose on Day 1 and Week 4 and post-dose on Weeks 4, 6, 8 and 12

07

Results

Posted Feb 28, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboLuvadaxistat 50 Milligrams (mg)Luvadaxistat 125 mgLuvadaxistat 500 mg
Started87585655
Completed76535247
Not completed11548
Withdrew: Adverse event2011
Withdrew: Lost to follow-up1000
Withdrew: Withdrawal by subject4323
Withdrew: Unsatisfactory therapeutic response1000
Withdrew: Noncompliance with study drug during the dbtp1211
Withdrew: Other2003

Outcome measures

PrimaryChange From Baseline on the PANSS NSFS at Week 12

PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS NSFS subscale consists of 7 items which assess the negative symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as least squares (LS) mean change from baseline at Week 12, determined using a mixed model for repeated measures (MMRM). A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline on the PANSS NSFS at Week 12
scores on a scalePlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Change From Baseline on the PANSS NSFS at Week 12-3.1 ± 0.44-3.3 ± 0.52-3.4 ± 0.51-2.5 ± 0.55
Statistical analysis
  • Placebo vs Luvadaxistat 50 mg · Mixed Models Analysis · p = 0.426 · Ls mean difference: -0.1 · 95% CI -1.4 to 1.2
  • Placebo vs Luvadaxistat 125 mg · Mixed Models Analysis · p = 0.725 · Ls mean difference: -0.2 · 95% CI -1.5 to 1.1
  • Placebo vs Luvadaxistat 500 mg · Mixed Models Analysis · p = 0.808 · Ls mean difference: 0.6 · 95% CI -0.7 to 1.9
SecondaryChange From Baseline on the PANSS NSFS at Week 4 and Week 8

PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS NSFS subscale consists of 7 items which assess the negative symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Weeks 4 and 8, determined using a MMRM. A negative change from baseline indicates improvement.

Time frame:
Baseline and Weeks 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline on the PANSS NSFS at Week 4 and Week 8
scores on a scalePlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Change at Week 4-1.7 ± 0.32-1.6 ± 0.39-1.8 ± 0.38-1.4 ± 0.40
Change at Week 8-2.8 ± 0.39-2.2 ± 0.46-2.6 ± 0.45-2.3 ± 0.49
SecondaryChange From Baseline on the Brief Negative Symptom Scale (BNSS) Total Score (12-item) at Week 12

The BNSS is a 13-item instrument that measures 5 domains of negative symptoms: blunted affect, alogia, asociality, anhedonia and avolition. All items in the BNSS are rated on a 7-point (0-6) scale, with anchor points generally ranging from symptoms being absent (0) to severe (6). Here, the BNSS total score (12-item, excluding item 4) was calculated by summing the 12 individual items; total score range of 0 to 72, where a higher score indicates higher severity of negative symptoms. Participants required a BNSS total score ≥28 to be eligible for the study (excluding item 4). Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline on the Brief Negative Symptom Scale (BNSS) Total Score (12-item) at Week 12
scores on a scalePlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Change From Baseline on the Brief Negative Symptom Scale (BNSS) Total Score (12-item) at Week 12-7.1 ± 1.04-8.9 ± 1.22-8.0 ± 1.22-6.0 ± 1.30
SecondaryChange From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Week 12

BACS is a cognition assessment battery and includes brief assessments of reasoning and problem solving, verbal fluency, attention, verbal memory, working memory and motor speed. The primary measure from each test is standardized by creating T-scores whereby the mean of the test session of a healthy person is set to 50 and the standard deviation set to 10. A composite T-score is calculated by averaging the 6 standardized primary measures. The composite T-score indicates how much higher or lower the participants cognition is compared to a healthy person. Lower T-scores are indicative of lower cognitive performance. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Day 12, determined using a MMRM.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · T-score
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Week 12
T-scorePlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Week 122.3 ± 0.834.6 ± 0.973.5 ± 0.962.3 ± 1.04
SecondaryChange From Baseline on the Clinical Global Impression-Schizophrenia Severity (CGI-SCH-S) Negative Symptoms Score at Week 12

The CGI-SCH scale is an adapted version of the CGI scale that is designed to assess global illness status in participants with schizophrenia. CGI-SCH-S is a 7-point scale that requires the investigator to rate the severity of the participant's illness at the time of assessment. Here, CGI-SCH-S negative symptoms score assesses the severity of illness for negative symptoms on the following 7-point scale: 1. normal, not at all ill; 2. borderline mentally ill; 3. mildly ill; 4. moderately ill; 5. markedly ill; 6. severely ill; or 7. among the most extremely ill. Baseline was defined as the last observed value before the first dose of study treatment. The number of participants with each CGI-SCH-S negative symptoms score at baseline and at Week 12 is reported.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Change From Baseline on the Clinical Global Impression-Schizophrenia Severity (CGI-SCH-S) Negative Symptoms Score at Week 12
ParticipantsPlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Baseline: Normal, not at all ill (1)0000
Baseline: Borderline mentally ill (2)0010
Baseline: Mildly ill (3)3313
Baseline: Moderately ill (4)36282522
Baseline: Markedly ill (5)26182018
Baseline: Severely ill (6)6222
Baseline: Among the most extremely ill (7)0000
Week 12: Normal, not at all ill (1)0000
Week 12: Borderline mentally ill (2)1323
Week 12: Mildly ill (3)13141211
Week 12: Moderately ill (4)34222118
Week 12: Markedly ill (5)20111312
Week 12: Severely ill (6)3111
Week 12: Among the most extremely ill (7)0000
SecondaryClinical Global Impression Schizophrenia Improvement (CGI-SCH-I) Negative Symptoms Score at Week 12

The CGI-SCH-I assesses the participant's improvement (or worsening). CGI-SCH-I requires the investigator to assess the participant's condition relative to baseline on a 7-point scale. Here, CGI-SCH-I negative symptoms score assesses the improvement for negative symptoms on the following scale: very much improved; 2. much improved; 3. minimally improved; 4. no change; 5. minimally worse; 6. much worse; or 7. very much worse. Baseline was defined as the last observed value before the first dose of study treatment. The number of participants with each CGI-SCH-I negative symptoms score at Week 12 is reported.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Clinical Global Impression Schizophrenia Improvement (CGI-SCH-I) Negative Symptoms Score at Week 12
ParticipantsPlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
1 - Very much improved0000
2 - Much improved1013125
3 - Minimally improved29191921
4 - No change32191618
5 - Minimally worse0021
6 - Much worse0000
7 - Very much worse0000
SecondaryChange From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Score at Week 12

The SCoRS is an interview-based measure of cognitive functioning that is developed to specifically assess aspects of cognitive functioning in participants with schizophrenia. The items assess the 7 cognitive domains of attention, memory, reasoning and problem solving, working memory, processing speed, language functions and social cognition. The SCoRS total score is the sum of the 20 items and varies from 20 to 80 with 20 being the best outcome and 80 being the worst. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Score at Week 12
scores on a scalePlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Change From Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Score at Week 12-1.6 ± 0.66-3.8 ± 0.77-2.3 ± 0.77-1.8 ± 0.83
SecondaryChange From Baseline on the PANSS Total Score at Week 12

PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline on the PANSS Total Score at Week 12
scores on a scalePlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Change From Baseline on the PANSS Total Score at Week 12-6.2 ± 1.00-7.2 ± 1.19-6.8 ± 1.18-5.0 ± 1.26
SecondaryChange From Baseline on the PANSS Positive Symptom Factor Score (PSFS) at Week 12

PANSS assesses the positive symptoms, negative symptoms and general psychopathology associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Here, the PANSS PSFS subscale consists of 7 items which assess the positive symptoms with subscale score ranging from 7 to 49, where a higher score indicates greater severity. Baseline was defined as the last observed value before the first dose of study treatment. Results are reported as LS mean change from baseline at Week 12, determined using a MMRM. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · scores on a scale
Change From Baseline on the PANSS Positive Symptom Factor Score (PSFS) at Week 12
scores on a scalePlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Change From Baseline on the PANSS Positive Symptom Factor Score (PSFS) at Week 12-0.8 ± 0.33-1.3 ± 0.39-1.3 ± 0.39-0.6 ± 0.42
SecondaryLuvadaxistat Plasma Concentrations

Blood samples were collected at pre-specified timepoints and plasma concentrations of luvadaxistat were measured. At Week 4, assessments were categorized as pre-dose or post-dose according to actual sampling time. Due to this, some participants may have had more than 1 record summarized for Week 4 pre-dose or Week 4 post-dose. Mean concentration on each visit was averaged from the observations over the time span of 24 hours post-dose or pre-dose.

Time frame:
Pre-dose on Day 1 and Week 4 and post-dose on Weeks 4, 6, 8 and 12
Reported as:
Mean · nanograms / milliliter
Luvadaxistat Plasma Concentrations
nanograms / milliliterLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
Day 1 - Pre-dose0.0 ± 0.000.0 ± 0.000.0 ± 0.00
Week 4 - Pre-dose22.5 ± 44.44106.5 ± 197.61345.2 ± 653.08
Week 4 - Post-dose79.0 ± 115.75229.8 ± 368.27480.2 ± 717.15
Week 683.60 ± 123.38183.60 ± 257.44409.3 ± 502.26
Week 8109.3 ± 144.76202.1 ± 294.60366.80 ± 473.74
Week 1261.50 ± 113.94185.62 ± 258.73356.0 ± 461.42

Adverse events

Collected over 12-week double-blind treatment period and up to 30 days follow-up: Day 1 up to Day 114.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/87 (0%)4/87 (4.6%)4/87 (4.6%)
Luvadaxistat 50 mg0/58 (0%)0/58 (0%)0/58 (0%)
Luvadaxistat 125 mg0/56 (0%)1/56 (1.8%)5/56 (8.9%)
Luvadaxistat 500 mg0/55 (0%)0/55 (0%)2/55 (3.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
SchizophreniaPsychiatric disorders0/870/581/560/55
Psychotic disorderPsychiatric disorders1/870/580/560/55
RhabdomyolysisMusculoskeletal and connective tissue disorders1/870/580/560/55
COVID-19Infections and infestations1/870/580/560/55
Tooth abscessInfections and infestations1/870/580/560/55
Most frequent other events
Most frequent other events
EventPlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mg
HeadacheNervous system disorders4/870/585/562/55

Baseline characteristics

The Full Analysis Set (FAS) will included all participants who were randomized and received at least 1 dose of the study drug during the Double-Blind Treatment Period.

Age, Categorical
Age, Categorical(Participants)PlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mgTotal
<=18 years00000
Between 18 and 65 years87585655256
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mgTotal
Female2420222288
Male63383433168
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mgTotal
Hispanic or Latino32218
Not Hispanic or Latino191218857
Unknown or Not Reported65443646191
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLuvadaxistat 50 mgLuvadaxistat 125 mgLuvadaxistat 500 mgTotal
American Indian or Alaska Native20103
Asian20305
Native Hawaiian or Other Pacific Islander00055
Black or African American1099028
White70464250208
More than one race00000
Unknown or Not Reported33107
08

Study locations

54 sites
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845, United States
  • Synergy Clinical Research Center
    Lemon Grove, California 91945, United States
  • Semel Institute for Neuroscience and Human Behavior
    Los Angeles, California 90048, United States
  • Excell Research
    Oceanside, California 92056, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Artemis Institute for Clinical Research, LLC
    San Diego, California 92103, United States
  • Connecticut Mental Health Center - Yale University
    New Haven, Connecticut 06519, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • The Dr. Alan & Diane Breier Prevention and Recovery Center for Early Psychosis
    Indianapolis, Indiana 46202, United States
  • Center for Behavioral Health, LLC
    Gaithersburg, Maryland 20877, United States
  • Cherry Health
    Grand Rapids, Michigan 49503, United States
  • Manhattan Psychiatric Center
    New York, New York 10027, United States
  • Research Strategies of Memphis, LLC
    Memphis, Tennessee 38119, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
  • State Psychiatric Hospital - Lovech
    Lovech, 5500, Bulgaria
  • State Psychiatric Hospital "Sv. Ivan Rilski", Novi Iskar
    Novi Iskar, 1282, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
  • Medical Centre "Sv. Naum"
    Sofia, 1113, Bulgaria
  • DCC "Sv. Vrach and Sv. Sv. Kuzma and Damyan", OOD
    Sofia, 1408, Bulgaria
  • DCC "Mladost M" - Varna, OOD
    Varna, 9020, Bulgaria
  • Mental Health CenterVratsa EOOD
    Vratsa, 3000, Bulgaria
  • Narodni ustav dusevniho zdravi
    Klecany, 250 67, Czechia
  • A-SHINE s.r.o.
    Plzen, 31200, Czechia
  • CLINTRIAL s.r.o.
    Praha 10, 100 00, Czechia
  • PRAGTIS s.r.o.
    Praha 2, 120 00, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 00, Czechia
  • MUDr. Simona Papezova s.r.o.
    Praha 9, 190 00, Czechia
  • Zentralinstitut fuer Seelische Gesundheit
    Mannheim, Baden Wuerttemberg 68159, Germany
  • Studienzentrum Nordwest
    Westerstede, Niedersachsen 26655, Germany
  • Universitaetsklinikum Leipzig AoeR
    Leipzig, Sachsen 04103, Germany
  • Charite Universitaetsmedizin Berlin - Campus Charite Mitte
    Berlin, 10117, Germany
  • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
    Bari, 70124, Italy
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
    Brescia, 25100, Italy
  • Azienda Ospedaliera Universitaria- Universita degli Studi della Campania Luigi Vanvitelli
    Napoli, 80138, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino
    Torino, 10124, Italy
  • Przychodnia Srodmiescie Sp. z o. o.
    Bydgoszcz, 85-080, Poland
  • NZOZ Syntonia
    Gdynia, 81-361, Poland
  • Care Clinic
    Katowice, 40-060, Poland
  • NZOZ Poradnia Zdrowia Psychicznego
    Kobierzyce, 55-040, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-363, Poland
  • Medycyna Milorzab
    Lodz, 93-118, Poland
  • Centrum Medyczne "Luxmed" Sp. z o.o.
    Lublin, 20-080, Poland
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Regional Psychoneurological Hospital #3
    Ivano Frankivsk, 76011, Ukraine
  • CIH Kharkiv Regional Clinical Psychiatric Hospital #3
    Kharkiv, 61068, Ukraine
  • Kyiv CH on Railway Transport #2 of Branch Center of Healthcare Public Company Ukr Railway
    Kyiv, 03049, Ukraine
  • CI Kirovograd RPH Male dept#11,Female dep#17 Donetsk NMU
    Nove, Kropyvnytskiy, 25491, Ukraine
  • Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
    Ternopil, 46020, Ukraine
  • Transcarpathian Regional Narcological Dispensary
    Uzhgorod, 88000, Ukraine
  • Zhytomyr Regional Psychiatric Hospital #1
    Zarichany Vil., 12440, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2020, 35 months.

Results were first posted in Feb 2024, 3 years 1 month after primary completion. A results delay was requested in Dec 2021.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 35 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2017
First posted
Dec 26, 2017
StartActual
Jan 4, 2018
Primary completionActual
Dec 29, 2020
CompletionActual
Jan 12, 2021
Results delay requested
Dec 7, 2021
Results first posted
Feb 28, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03382639
Collaborators
Takeda
Responsible party
Sponsor
First posted
Dec 26, 2017
Start date
Jan 4, 2018
Primary completion
Dec 29, 2020
Completion
Jan 12, 2021
Results posted
Feb 28, 2024
Last update
Feb 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luvadaxistat

Start the discussion